LAB — STANDARD BIOTOOLS INC.

Nasdaq · Unknown · Unknown · CIK 1162194 ·
Last close
$1.09
Market Cap
$425.50M
52W High
$1.18
52W Low
$0.87
ADV30
2,577,861
Next earnings
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 21,146,000 11,308,000 -9,416,000 127,068,000 639,114,000 265,772,000 77,991,000
Dec 2025 23,795,000 11,382,000 -21,924,000 19,283,000 567,754,000 120,863,000 143,463,000
Sep 2025 19,552,000 9,484,000 -23,467,000 -34,687,000 539,636,000 129,418,000 139,977,000
Jun 2025 21,762,000 10,628,000 -23,699,000 -33,459,000 556,965,000 158,617,000 132,430,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-74,343,000
Investing CF
$27,409,000
Financing CF
$570,000
CapEx
$-8,303,000
Dividends Paid
Buybacks
$0
EPS Diluted TTM
$-0.20
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,260,547,000
Inventory
$19,981,000
Receivables
$13,431,000
ST Investments
$66,712,000
EBIT TTM
$-99,371,000
Pretax Income TTM
$-99,397,000
Interest Exp TTM
$26,000
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$86,255,000
EBITDA
$-68,210,000
Free Cash Flow
$-13,438,500
Enterprise Value
$-183,750
Total Cash
$455,176,000
Total Debt
$29,491,000
Shares Out
390,368,119
Trailing EPS
$-0.13
Book Value
$1.44
ROE
-9.9%
ROA
-8.1%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 85,331,000 -93,305,000 -74,896,000 567,754,000 143,463,000 -74,343,000
Dec 2024 91,008,000 -87,006,000 -138,885,000 612,345,000 140,623,000 -143,454,000
Dec 2023 106,340,000 -63,039,000 -74,656,000 323,067,000 471,118,000 -43,287,000
Dec 2022 97,948,000 -102,616,000 -190,098,000 390,310,000 471,777,000 -89,370,000

TTM Snapshot

Revenues TTM
$121,365,000
NetIncome TTM
$-109,017,000
OpCashFlow TTM
$0
Assets (Latest)
$390,310,000
Forward EPS
$-0.01

News headlines (Yahoo Finance, 1h cache)

Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates
2026-05-06 00:30 · Yahoo
Standard BioTools Reports First Quarter 2026 Financial Results
2026-05-05 20:05 · Yahoo
Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026
2026-04-21 11:00 · Yahoo
Standard BioTools (LAB) is One of the Best Life Sciences Penny Stocks, Here is Why
2026-04-14 05:29 · Yahoo
Labrador Gold Welcomes Recent Announcement by the Ontario Government Concerning Accelerated Development of the Ring of Fire Road
2026-03-26 11:00 · Yahoo
Labrador Gold Announces Closing of Change of Business and Acquisition of Units of Northern Shield
2026-03-09 14:15 · Yahoo
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million
2026-02-27 16:18 · Yahoo
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million
2026-02-27 16:12 · Yahoo
CORRECTION – Labrador Gold Announces Voting Results of the 2026 Annual General and Special Meeting of Shareholders
2026-02-25 14:42 · Yahoo
Labrador Gold Announces Voting Results of the 2026
2026-02-24 23:33 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.